Lower dose and weekly schedules of selinexor in multiple myeloma – updated evidence on safety and efficacy

By afschroeder • October 8, 2025

Baljevic M, Schiller G, Mark TM, Van Domelen DR, Gasparetto C. Lower dose and weekly schedules of selinexor in multiple myeloma - updated evidence on safety and efficacy. Front Oncol. 2025 Sep 22;15:1649493. doi: 10.3389/fonc.2025.1649493. PMID: 41059291; PMCID: PMC12497632.

Tags: antagonists, clinical efficacy, combination drug therapy, drug administration schedules, exportin 1, Hematology/Oncology, inhibitors, Multiple myeloma, Publications, selinexor

Pembrolizumab plus lenvatinib with belzutifan or quavonlimab as first-line therapy for advanced renal-cell carcinoma: randomized open-label phase 3 LITESPARK-012 study

Rini BI, Choueiri TK, Voss MH, Burotto M, Oldenburg J, Gurney HP, Ferguson TR, Hammers H, Albiges L, Ürün Y, Romero Diaz RI, Özgüroğlu M,[...]

Systemic Mastocytosis With Associated Acute Myeloid Leukemia Identified After Induction Therapy: A Case Report and Literature Review

Han J, Ghamsari F, Yan J, Kim P. Systemic Mastocytosis With Associated Acute Myeloid Leukemia Identified After Induction Therapy: A Case Report and Literature Review.[...]

Asia-Pacific Transplant Oncology Symposium 2024: Expert Statements on the Current State and Future Direction of Hepatobiliary Surgical and Transplant Oncology

Law JH, Xie K, Yang J, Kudo M, Muthiah MD, Mehta N, Bhoori S, Pinato DJ, Chee CE, Hatano E, Line PD, Chan SL, Doyle[...]